Edition:
United States

Bio Rad Laboratories Inc (BIO.N)

BIO.N on New York Stock Exchange

161.96USD
29 Sep 2016
Change (% chg)

$-0.30 (-0.18%)
Prev Close
$162.26
Open
$162.06
Day's High
$162.46
Day's Low
$161.22
Volume
23,232
Avg. Vol
25,954
52-wk High
$162.49
52-wk Low
$123.00

Latest Key Developments (Source: Significant Developments)

Bio Rad Laboratories reports Q2 profit $0.61 per share
Wednesday, 3 Aug 2016 04:15pm EDT 

Bio Rad Laboratories Inc : Second-Quarter reported revenues were $516.8 million, an increase of 2.1 percent . Bio-Rad reports second-quarter 2016 financial results .Net income for Q2 of 2016 was $18.0 million, or $0.61 per share.  Full Article

Bio-Rad Laboratories Inc's TANGO infinity Receives FDA 510(k) Clearance for U.S. Markets
Monday, 21 Dec 2015 04:21pm EST 

Bio-Rad Laboratories:Received U.S. Food and Drug Administration clearance to market its TANGO infinity system in the U.S.The system automates routine blood typing and screening testing procedures for patients and donors.  Full Article

Bio-Rad Laboratories Inc announces U.S. FDA pre-market approval for BioPlex 2200 HIV Ag-Ab Assay
Tuesday, 28 Jul 2015 04:15pm EDT 

Bio-Rad Laboratories Inc:Received U.S. Food and Drug Administration pre-market approval to offer its BioPlex 2200 HIV Ag-Ab assay, the company's 5th generation HIV diagnostic test.  Full Article

Bio-Rad Laboratories receives premarket application approval for Geenius HIV 1/2 supplemental assay
Tuesday, 18 Nov 2014 04:15pm EST 

Bio-Rad Laboratories Inc:Receives Premarket Application approval from the U.S. Food and Drug Administration for Bio-Rad's Geenius HIV 1/2 Supplemental Assay (test).Geenius HIV 1/2 Supplemental Assay is a single-use immunochromatographic assay intended for use as an additional test to confirm the presence of and differentiate antibodies to Human Immunodeficiency Virus Types 1 and 2 (HIV-1 and HIV-2).  Full Article

Bio-Rad Laboratories Inc reaffirms FY 2014 revenue guidance-Conference Call
Tuesday, 4 Nov 2014 05:00pm EST 

Bio-Rad Laboratories Inc:Says it continue to anticipate FY 2014 currency neutral sales growth of around 2.5 pct and in line with the guidance set at the beginning of the year.Reported revenue of $2.132 bln in FY 2013.FY 2014 revenue of $2.179 bln - Thomson Reuters I/B/E/S.  Full Article

BRIEF-Bio Rad Laboratories reports Q2 profit $0.61 per share

* Second-Quarter reported revenues were $516.8 million, an increase of 2.1 percent